Zacks Investment Research
08 Oct 2026, 22:51 UTC · 1h ago
Impact · against what's priced in
The article provides no new catalysts for ADMA, as the highlighted EPS and revenue growth targets are already reflected in the consensus estimates. The stock's current valuation discount relative to its industry peers remains a known structural factor rather than a new development.
No priced-in read yet
What the story claims
3 claims · scored −1 bearish … +1 bullish · 0 new · 3 priced in
The consensus EPS estimate for Adma Biologics' upcoming quarter is $0.19, an 18.75% increase year-over-year.
Priced inanalysis of consensus estimates
So whatA beat on this $0.19 target would likely trigger a multiple expansion toward the industry average P/E of 23.26.
More positive than 66% of claims this week
Adma Biologics has a Forward P/E ratio of 13.06, which is a discount compared to its industry's Forward P/E of 23.26.
Continue reading
5 related stories
The reported expectations for $0.19 quarterly EPS and $0.78 annual EPS are current consensus estimates and do not represent a deviation from what the market is already anticipating.
Read from the article alone
Scored by the NIS engine · methodology.
Priced incurrent valuation analysis
So whatThe stock trades at roughly 56% of its industry peer average, suggesting significant upside if valuation gaps close.
More positive than 54% of claims this week
The full-year fiscal forecast predicts earnings of $0.78 per share and revenue of $536.82 million, representing growth of 30% and 5.22% respectively.
Priced inZacks Consensus Estimates
So whatThe 30% EPS growth target indicates expanding net margins as revenue growth is trailing at only 5.22%.
More positive than 54% of claims this week
Which stocks this story touches
More positive than 65% of ticker scores this week
The company outperformed the S&P 500 and is expecting year-over-year growth in both EPS and revenue.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
1h ago
—
ADMA hasn't traded since this ran. Last close $10.33 (Oct 8); the reaction starts at the next open.
ADMA chart →
